Antimicrobial activity of quinoxaline 1,4-dioxide with 2- and 3-substituted derivatives

Microbiological Research

Volumn 169, Issue 4, 2014, Pages 287-293

  Vieira, Mónica ^a,b   Pinheiro, Cátia ^b   Fernandes, Rúben ^b,c   Noronha, João Paulo ^a   Prudêncio, Cristina ^b,c,d  

^a UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^b POLYTECHNIC INSTITUTE OF PORTO   (Portugal)

^c University of Porto   (Portugal)

^d CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

Antimicrobial activity; Cellular viability; Minimum inhibitory concentration; Quinoxaline N,N dioxide derivatives

Indexed keywords

ANTIINFECTIVE AGENT; QUINDOXIN; QUINOXALINE DERIVATIVE;

ANTIMICROBIAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CELL VIABILITY; CHEMISTRY; DRUG EFFECT; ESCHERICHIA COLI; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; MINIMUM INHIBITORY CONCENTRATION; QUINOXALINE N,N-DIOXIDE DERIVATIVES; SACCHAROMYCES CEREVISIAE; STAPHYLOCOCCUS AUREUS;

ANTIMICROBIAL ACTIVITY; CELLULAR VIABILITY; MINIMUM INHIBITORY CONCENTRATION; QUINOXALINE N,N-DIOXIDE DERIVATIVES;

ANTI-INFECTIVE AGENTS; CANDIDA ALBICANS; ESCHERICHIA COLI; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; QUINOXALINES; SACCHAROMYCES CEREVISIAE; STAPHYLOCOCCUS AUREUS;

EID: 84894308305     PISSN: 09445013     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.micres.2013.06.015     Document Type: Article

References (36)

1. Acree W.E., Powell J.R., Tucker S.A., daSilva M., Matos M.A.R., Goncalves J.M. Thermochemical and theoretical study of some quinoxaline 1,4-dioxides and of pyrazine 1,4-dioxide. J Org Chem 1997, 62(11):3722-3726.
2. Alanis A.J. Resistance to antibiotics: are we in the post-antibiotic era?. Arch Med Res 2005, 36(6):697-705.
3. Barford J.P. A general model for aerobic yeast growth: batch growth. Biotechnol Bioeng 1990, 35(9):907-920.
4. Blondeau J.M., Laskowski R., Bjarnason J., Stewart C. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms. Int J Antimicrob Agents 2000, 14(1):45-50.
5. 2+ in the S. cerevisiae cells. Colloids Surf B: Biointerfaces 2003, 35-42.
6. Burguete A., Pontiki E., Hadjipavlou-Litina D., Ancizu S., Villar R., Solano B., et al. Synthesis and biological evaluation of new quinoxaline derivatives as antioxidant and anti-inflammatory agents. Chem Biol Drug Des 2011, 77(4):255-267.
7. Butaye P., Devriese L.A., Haesebrouck F. Differences in antibiotic resistance patterns of Enterococcus faecalis and Enterococcus faecium strains isolated from farm and pet animals. Antimicrob Agents Chemother 2001, 45(5):1374-1378.
8. Carta A., Paglietti G., Nikookar M.E.R., Sanna P., Sechi L., Zanetti S. Novel substituted quinoxaline 1,4-dioxides with in vitro antimycobacterial and anticandida activity. Eur J Med Chem 2002, 37(5):355-366.
9. Chang-Li X., Hou-Kuhan T., Zhau-Hua S., Song-Sheng Q., Yao-Ting L., Hai-Shui L. Microcalorimetric study of bacterial growth. Thermochim Acta 1988, 123(0):33-41.
10. De Clercq E. Development of resistance of human immunodeficiency virus (HIV) to anti-HIV agents: how to prevent the problem?. Int J Antimicrob Agents 1997, 9(1):21-36.
11. Fernandes R., Vieira M., Ferraz R., Prudencio C. Bloodstream infections caused by multidrug resistant Enterobacteriaceae: report from two Portuguese hospitals. J Hosp Infect 2008, 70(1):93-95.
12. Fernandes R., Gestoso A., Freitas J.M., Santos P., Prudencio C. High resistance to fourth-generation cephalosporins among clinical isolates of Enterobacteriaceae producing extended-spectrum beta-lactamases isolated in Portugal. Int J Antimicrob Agents 2009, 33(2):184-185.
13. Fernandes R., Amador P., Prudencio C. beta-Lactams: chemical structure, mode of action and mechanisms of resistance. Rev Med Microbiol 2013, 24(1):7-17.
14. Gomes J.R.B., Sousa E.A., Gonçalves J.M., Monte M.J.S., Gomes P., Pandey S., et al. Energetics of the NO bonds in 2-hydroxyphenazine-di-N-oxide. J Phys Chem B 2005, 109(33):16188-16195.
15. Gomes J.R.B., Sousa E.A., Gomes P., Vale N., Gonçalves J.M., Pandey S., et al. Thermochemical studies on 3-methyl-quinoxaline-2-carboxamide-1,4-dioxide derivatives: enthalpies of formation and of NO bond dissociation. J Phys Chem B 2007, 111(8):2075-2080.
16. Gradelski E., Kolek B., Bonner D.P., Valera L., Minassian B., Fung-Tomc J. Activity of gatifloxacin and ciprofloxacin in combination with other antimicrobial agents. Int J Antimicrob Agents 2001, 17(2):103-107.
17. Harakeh S., Diab-Assef M., El-Sabban M., Haddadin M., Gali-Muhtasib H. Inhibition of proliferation and induction of apoptosis by 2-benzoyl-3-phenyl-6,7-dichloroquinoxaline 1,4-dioxide in adult T-cell leukemia cells. Chem-Biol Interact 2004, 148(3):101-113.
18. Haykal J., Fernainy P., Itani W., Haddadin M., Geara F., Smith C., et al. Radiosensitization of EMT6 mammary carcinoma cells by 2-benzoyl-3-phenyl-6,7-dichloroquinoxatine 1,4-dioxide. Radiother Oncol 2008, 86(3):412-418.
19. Hossain M.M., Muhib M.H., Mia M.R., Kumar S., Wadud S.A. In vitro antioxidant potential study of some synthetic quinoxalines. Bangladesh Med Res Counc Bull 2012, 38(2):47-50.
20. Moellering R.C. Discovering new antimicrobial agents. Int J Antimicrob Agents 2011, 37(1):2-9.
21. Moreno A., Bello H., Guggiana D., Dominguez M., Gonzalez G. Extended-spectrum beta-lactamases belonging to CTX-M group produced by Escherichia coli strains isolated from companion animals treated with enrofloxacin. Vet Microbiol 2008, 129(1-2):203-208.
22. Neu H.C., Labthavikul P. Comparative in vitro activity of N-formimidoyl thienamycin against gram-positive and gram-negative aerobic and anaerobic species and its beta-lactamase stability. Antimicrob Agents Chemother 1982, 21(1):180-187.
23. Rex J. M44 A2. Method for antifungal disk diffusion susceptibility testing of yeast; approved guideline - second ed 2009, CLSI, Pennsylvania, USA.
24. Ribeiro da Silva M.D.M.C., Gomes J.R.B., Gonçalves J.M., Sousa E.A., Pandey S., Acree W.E. Thermodynamic properties of quinoxaline-1,4-dioxide derivatives: a combined experimental and computational study. J Org Chem 2004, 69(8):2785-2792.
25. Roe V.A. Antibiotic resistance: a guide for effective prescribing in women's health. J Midwifery Womens Health 2008, 53(3):216-226.
26. Sanna P., Carta A., Loriga M., Zanetti S., Sechi L. Preparation and biological evaluation of 6/7-trifluoromethyl(nitro)-, 6,7-difluoro-3-alkyl (aryl)-substituted-quinoxalin-2-ones. Part 3. Farmaco 1999, 54(3):169-177.
27. Santos S.M., Henriques M., Duarte A.C., Esteves V.I. Development and application of a capillary electrophoresis based method for the simultaneous screening of six antibiotics in spiked milk samples. Talanta 2007, 71(February (2)):731-737.
28. Sezonov G., Joseleau-Petit D., D'Ari R. Escherichia coli physiology in Luria-Bertani Broth. J Bacteriol 2007, 189(23):8746-8749.
29. Sykes R.B., Bonner D.P., Bush K., Georgopapadakou N.H. Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic gram-negative bacteria. Antimicrob Agents Chemother 1982, 21(1):85-92.
30. Vollaard E.J., Clasener H.A.L. Colonization resistance. Antimicrob Agents Chemother 1994, 38(March (3)):409-414.
31. Waring M.J., Ben-Hadda T., Kotchevar A.T., Ramdani A., Touzani R., Elkadiri S., et al. 2,3-Bifunctionalized quinoxalines: synthesis, DNA interactions and evaluation of anticancer, anti-tuberculosis and antifungal activity. Molecules 2002, 7(8):641-656.
32. M100 S15. Performance standards for antimicrobial susceptibility testing; fifteenth informational supplement. Suppl. ed 2005, CLSI, Pennsylvania, USA. M. Wilder (Ed.).
33. Wilder w. M7-A7. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard - Seventh ed 2006, CLSI.
34. Witte W., Cuny C., Klare I., Nuebel U., Strommenger B., Werner G. Emergence and spread of antibiotic-resistant Gram-positive bacterial pathogens. Int J Med Microbiol 2008, 298(5-6):365-377.
35. Zanetti S., Sechi L.A., Molicotti P., Cannas S., Carta A., Bua A., et al. In vitro activity of new quinoxalin 1,4-dioxide derivatives against strains of Mycobacterium tuberculosis and other mycobacteria. Int J Antimicrob Agents 2005, 25(2):179-181.
36. Zwietering M.H., Jongenburger I., Rombouts F.M., van't Riet K. Modeling of the bacterial growth curve. Appl Environ Microbiol 1990, 56(6):1875-1881.